We have already launched a number of achievable items in the regulatory review of drugs and devices. We are planning to have the entire initiative completed by the end of 2021.
However, we have already launched a number of things. We now offer aligned reviews between the regulator and the HTA to all drug manufacturers. We are providing early advice in drug development to sponsors in parallel with the HTAs. We are developing specific regulations that will allow us, for certain products, which has a great applicability to orphan drugs, to recognize a foreign regulator's decision to approve.
Those are—